[1] Liu L, Zheng YH, Han L, et al. Efficacy and safety of the oxaliplatin-based chemotherapy in the treatment of advanced primary hepatocellular carcinoma. Medicine, 2016, 95: e4993.
[2] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65:87-108.
[3] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015, 136: E359-E386.
[4] Ji J, Tang J, Deng L, et al. LINC00152 promotes proliferation in hepatocellular carcinoma by targeting EpCAM via the mTOR signaling pathway. Oncotarget, 2015, 6: 42813-42824.
[5] Liu H, Liu Y, Liu W, et al. EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma. Nat Commun, 2015, 6:8494.
[6] Zhang SM, Zhang N. Research progress of hepatocellular carcinoma chemotherapy. Chin J New Drugs Clin Rem, 2015, 34: 93-98.
[7] Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from asia. J Clin Oncol, 2013, 31:3501-3508.
[8] Brujx J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 2017, 389:56-66.
[9] Masatoshi Kudo, Richard S Finn, Shukui Qin, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.The Lancet, 2017, 391:1163-1173.
[10] Butterfield LH, Economou JS, Gamblin TC, et al. Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients. J Transl Med, 2014, 12:86.
[11] Nemunaitis J, Barve M, Orr D, et al. Summary of bi-shRNAfurin/GM-CSF augmented autologous tumor cell immunotherapy (FANGTM) in advanced cancer of the liver. Oncology, 2014, 87: 21-29.
[12] Duffy AG, Ulahannan SV, Makorovarusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.J Hepatol, 2017,66:545-551.
[13] 叶因涛,王晨,孙蓓.PD-1/PD-L1抑制剂在肿瘤免疫治疗中的研究进展.中国肿瘤临床,2015, 42: 1178-1182.
[14] Brahmer JR, Hammers H, Lipson EJ. Nivolumab: targeting PD-1 to bolster antitumor immunity. Future Oncol, 2015, 11:1307-1326.
[15] Melero I, Crocenzi TS, Welling TH. Phase I/II safety and anti tumor activity of nivolumab in patients with advanced hepatocellular carcinoma(HCC): CA209-040. J Clin Oncol, 2015, 33: LBA101.
[16] El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation andexpansion trial.Lancet,2017,389:2492-2502.
[17] Andrew X Zhu, Richard S Finn, Julien Edeline, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.Lancet Oncol, 2018,19: 940-952.
[18] Lee JH, Lee J, Lim Y, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology, 2015, 148: 1383-1391.
[19] Pan K, Li YQ, Wang W, et al. The efficacy of cytokine-induced killer cell infusion as adjuvant therapy for postoperative hepatocellular carcinoma patients. Ann Surg Oncol, 2013, 20: 4305-4311.
[20] Cui J, Wang N, Zhao H, et al. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma. Int J Cancer, 2014, 134: 342-351.
[21] Gao H, Li K, Tu H, et al. Development of cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res, 2014, 20: 6418-6428. |
